Monte Wiltse
Monte Wiltse is the president and CEO of Fujirebio Diagnostics Inc., a biotechnology company that developed the Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio, the first blood test cleared by the FDA to aid in the early detection of Alzheimer’s disease in the United States. Wiltse has emphasized the importance of early and accurate diagnosis in facilitating the development of new therapeutic interventions for Alzheimer’s, particularly as the prevalence of the disease increases with an aging population.
Global Media Ratings
Countries Mentioned
No country-level mention data available.
Interactive World Map
Each country's color is based on "Mentions" from the table above.
Recent Mentions
United States:
Fujirebio Diagnostics designed the blood test to help detect Alzheimer’s disease early, president and CEO Monte Wiltse said in a news release last year.
7